Literature DB >> 2032244

Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin.

B C Giovanella1, H R Hinz, A J Kozielski, J S Stehlin, R Silber, M Potmesil.   

Abstract

20-(S)-Camptothecin (CAM), a plant alkaloid, was tested against 13 human cancer xenograft lines carried by immunodeficient (nude) mice. The drug, formulated in 20% intralipid and given i.m., was more effective than any other clinically available drug tested. It was found that: (a) CAM, at nontoxic doses, suppressed growth and induced regression of cancer of the colon (3 lines), lung (4 lines), breast (2 lines), stomach (1 line), ovary (1 line), and malignant melanoma (2 lines); (b) the drug was equally effective administered i.m. or p.o. Both routes are significantly better than i.v. administration; (c) CAM is substantially more effective and less toxic than its sodium salt, which was unsuccessfully tested in cancer patients. CAM should be further tested against responsive cancers as a drug which is easy to isolate and formulate for large-scale studies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2032244

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

Review 1.  Camptothecin delivery methods.

Authors:  A Hatefi; B Amsden
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

2.  Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles.

Authors:  Jamie K Hu; Hee-Won Suh; Munibah Qureshi; Julia M Lewis; Sharon Yaqoob; Zoe M Moscato; Sofia Griff; Alison K Lee; Emily S Yin; W Mark Saltzman; Michael Girardi
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-16       Impact factor: 11.205

Review 3.  Topoisomerase I in multiple drug resistance.

Authors:  A Pessina
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Authors:  G N Schwartz; B A Teicher; J P Eder; T Korbut; S A Holden; G Ara; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  A method to determine the incorporation capacity of camptothecin in liposomes.

Authors:  Ann Mari Saetern; Gøril Eide Flaten; Martin Brandl
Journal:  AAPS PharmSciTech       Date:  2004-06-17       Impact factor: 3.246

6.  Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-alpha-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin.

Authors:  L Mu; T A Elbayoumi; V P Torchilin
Journal:  Int J Pharm       Date:  2005-10-19       Impact factor: 5.875

7.  Key Genes in Stomach Adenocarcinoma Identified via Network Analysis of RNA-Seq Data.

Authors:  Li Shen; Lizhi Zhao; Jiquan Tang; Zhiwei Wang; Weisong Bai; Feng Zhang; Shouli Wang; Weihua Li
Journal:  Pathol Oncol Res       Date:  2017-01-05       Impact factor: 3.201

Review 8.  Oral topoisomerase 1 inhibitors in adult patients: present and future.

Authors:  H A Gelderblom; M J DE Jonge; A Sparreboom; J Verweij
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

9.  Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.

Authors:  B A Teicher; S A Holden; V Khandakar; T S Herman
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

10.  Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania.

Authors:  A L Bodley; T A Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.